| 1 -0.17 (-14.53%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.34  |
1-year : | 1.95 |
| Resists | First : | 1.15 |
Second : | 1.66 |
| Pivot price | 0.69 |
|||
| Supports | First : | 0.32 |
Second : | 0.26 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 0.67 |
| MA(100) : | 1.48 |
MA(250) : | 1.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 87.7 |
D(3) : | 88.5 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 2.78 | Low : | 0.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IOBT ] has closed below upper band by 14.1%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.24 |
| Low: | 0.92 - 0.92 | 0.92 - 0.93 |
| Close: | 1.16 - 1.17 | 1.17 - 1.18 |
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Mon, 20 Oct 2025
19.4‑Month mPFS: IO Biotech Cylembio+KEYTRUDA Shows Subgroup Benefits, No Added Systemic Toxicity - Stock Titan
Wed, 08 Oct 2025
IO Biotech to announce Phase 3 melanoma treatment results By Investing.com - Investing.com Nigeria
Mon, 29 Sep 2025
FDA Recommends Against Cancer Vaccine BLA: IO Biotech's Cylembio Faces Setback, 50% Staff Cut - Stock Titan
Mon, 29 Sep 2025
IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine - Stocktwits
Mon, 29 Sep 2025
IO Biotech Faces FDA Setback with Cylembio; Plans New Study and Workforce Restructuring - Quiver Quantitative
Wed, 03 Sep 2025
IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 63.8 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -80.7 % |
| Return on Equity (ttm) | -212.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.04 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 49.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|